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Sinary In order to assess the accuracy of Scottish cancer registration data, a random sample of 2,200
registrations, attributed to the year 1990, was generated. Relevant medical records were available for review in
2,021 (92%) cases. Registration details were reabstracted from available records and compared with data in
the registry. Discreancies in identifying items of data (surname, forename, sex and date of birth) were found
in 3.5% of cases. Most were trivial and would not disturb record linkage. Discrepancy rates of 7.1% in post
code of residence at the time of diagnosis (excluding differences arising through boundary changes), 11.0% in
anniversary date (excluding differences of 6 weeks or less), 7.7% in histological verification status, 5.4% in
ICD-9 site codes (the first three digits) and 14.5% in ICD-O morphology codes (excluding 'inferred'
morphology codes) were recorded. Overall, serious discrepancies were judged to have occurred in 2.8% of
cases. In many respects, therefore, Scottish cancer registration data show a high level of accuracy that
compares favourably to the reported accuracy of the few other cancer registries undertaking such analyses.
The value of cancer registration data is largely dependent on
their accuracy and completeness. If available data are to be
interpreted with confidence, they need to be (and be seen to
be) of high quality (Joslin. 1990; Skeet. 1991). Although
several studies in Scotland have examined the accuracy of
cancer registration data. these have either been tumour
specific (Glass et al.. 1987: Gray et al.. 1987). Health Board
based (Lapham & Waugh. 1992) or both (Baijal et al., 1989).
The purpose of our study was to assess the overall accuracy
of Scottish cancer registration data.
The organisation of cancer registration in Scotland has
been described elsewhere (SHHD. 1990). In summary. five
regional registries collect data usually denrved from a source
document compiled by hospital discharge data-coding clerks
or from a histopathology report. In addition, the Registrar
General for Scotland supplies a quarterly listing of people
who have had any mention of cancer on their death certifi-
cates.
Tumours eligible for registration are: all malignant neo-
plasms (ICD-9 140-208), carcinoma in situ (ICD-9
230-234), neoplasms of uncertain behaviour (ICD-9
235-238) and neoplasms of unspecified nature (ICD-9 239).
Beyond this, eligibility criteria for registration of a tumour
are implicit rather than explicitly defined. However, it is
generally accepted that, for a tumour to be included in the
Scottish data set, the patient should have been resident in
Scotland for at least 6 months before diagnosis.
from death certificates only (DCOs) was sought through the
primary care divisions of health boards of residence.
For every case with available medical records, a single
observer (D.B.) reabstracted selected items ofdata, according
to the 1984 edition of the SMR 6 (Scottish Morbidity Record
6 - Cancer Registration) Coding Guide. In these guidelines.
the 'date treatment commenced' (anniversary date) is defined
by rules contained in the appendix to this paper. The Coding
Guide does not define histological verification. In the context
of this study it was taken literally to mean verification by
histology; cytological evidence, on its own, was not regarded
as histological verification.
To ensure that reabstracted details actually referred to the
originally registered tumour of the correct patient in every
case, reabstraction was not undertaken blindly.
Details of site and morphology were recorded as text and
later recoded blindly by a single observer (C.M.). Address at
the time of diagnosis was recorded and post code of
residence assigned using the Post code Address File.
For all registrations with obtainable medical records, the
reabstracted details were compared item by item against
those originally registered and any discrepancies noted.
Variants of identifying data items within the same set of
medical records were not counted as discrepancies unless
none of the versions corresponded to details originally
registered.
The statistical significance ofdifferences in proportions was
assessed using the chi-squared test: when the expected value
in any cell was below five. Fisher's exact test was applied.
Methods
A random sample of registrations of cancer in Scotland in
1990 was generated by computer. This year was chosen as it
was the most recent for which the data set had been closed.
Sample size was chosen on the basis that a sample of 2,000
should identify an error rate of 5% to within 95% confidence
intervals of 4.04-5.96%. Expecting that approximately 10%
of medical records might be unobtainable, the final sample
size chosen was 2,200 (6.9% of all registrations in 1990).
In most cases, access to the medical records of these
patients required a visit to the institution of registration
(usually, this refers to the institution where the diagnosis is
first established). Because of time constraints, only one
'round' of visits was feasible. Access to general practitioner
records of patients registered on the basis of information
Results
Representativeness ofthe sample
In terms of age distribution (by 10 year age bands), sex
distribution, broad diagnostic categories*, histological
verification status, proportion of DCO registrations and dist-
ribution by regional registry, there were no statistically
significant differences between the random sample of 2,200
registrations and all neoplasms registered in Scotland to
1990.
Of the sample, 2,021 (92%) had medical records available
for scrutiny. In terms of age distribution (three broad age
categories), sex distnrbution, broad diagnostic categories* and
*Broad diagnostic categories were ICD-9 140-149. 150-159.
160-169. 170-179. 180-189. 190-199. 200-208. other.
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histological verification status, there were no significant
differences between patients with or without available
medical records. However, there was a significntly higher
proportion of DCO registrations in the unobtainable
category (10.1% vs 1.9%, P<0.001). Medical records
availability varied by regional registry (88.5-95.4%): this
variation was also statistically significnt (P <0.005).
Identifying data
Comparing the original registration details with those re-
abstracted, there were 18 (0.9%) differences in surname spell-
ing, 20 (1.0%) in specified forename, eight (0.4%) in gender
assignment and 27 (1.3%) in date of birth. Only five of the
last would result in reallocation to a different 5 year age
band.
Post code discrepancies In 29 (1.4%) cases, it was impossi-
ble to verify the post code held by the Cancer Registry
because of inadequate address information in available
medical records or because place of residence at diagnosis
was unclear. Excluding boundary changes, there were 141
discrepancies (7.1% of the available sample) affecting post
code of residence. Eleven patients had been resident in Scot-
land for less than 6 months at diagnosis. Among remaining
discrepancies, seven were at area code level, 28 at district
level, 20 at sector level and 75 at unit level. Thus, only 66
(3.3%) registrations had discrepancies which would affect
analyses at the level of post code sector, an aggregation
commonly used for small area analysis in Scotland.
Implications for record linkage In Scotland, liniage of other
records with cancer registration data is currently performed
by computenrsed probabilistic matching (Kendrick & Clarke,
1993). If available, the following identifying items are used:
surname, forename, sex, date of birth and post code. The
probability of linkage is not reduced when post codes
disagree (since this may simply have resulted from change of
address). In this study, discrepancies of surname, forename,
sex and date of birth affected 70 individuals (three had more
than one discrepancy). Although the reabstracted records of
three patients failed to link with their orinal cancer registra-
tion records, all would ultimately have been linked by
computer-prompted clerical checking.
'Date treatment commenced' (anniversary date)
For the 1,998 records with relevant information available,
1,778 (89%) of anniversary dates lay within 6 weeks of
originally allocated dates. In this respect, there was also
evidence of significant variation by regional registry
(84-94%, P <0.001). However, the variation was not
significant when non-melanoma skin tumours (ICD-9 173)
were excluded from the malignant neoplasm (ICD-9
140-208) (88-95%, P =0.12).
Based on the reabstracted anniversary date, 1,890/1,998
(95%) cases were incident in 1990. The distribution of the
remaining cases (including DCOs) by year of onset is shown
in Table I.
Histological verification status
In 22 (1.1%) cases, there was insufficient detail in available
medical records to reach a definite conclusion about histo-
logical verification. Among remaining registrations, there
were 154 (7.7%) discrepancies in histological verification
status. Of these, 68 (4.2%) were reassigned to the histo-
logically verified category and 86 (55.8%)/. to the not histo-
logically verified category. However, 66 (76.7%) of the latter
cases had cytological verification of the diagnosis.
Site discrepancies
Three cases (0.1°/%) did not have adequate information in
their available medical records to permit confirmation or
amendment of the originally allocated subsite. In 645 (32%)
cases, a revised ICD-9 (WHO, 1977) site code was assigned.
Discrepancies in site coding were classified into broad
categories (Table II). Among major cancer sites [excluding
non-melanoma skin (ICD-9 173.-)], the highest proportions
of incomplete topographic assignment (subsite unspecified
recoded to a specific subsite) were in bladder (65%),
oesophagus (55%), lung (49%) and breast (47%). Many of
the site code disrepancies at three-digit level arose from
recoding to adjacent sites [for example, oesophagus (ICD-9
150.-) to stomach (ICD-9 151.-)], others through recoding
of specified primary sites to metastases and vice versa (Table
III).
Although the proportions of all types of site discrepancies
varied significantly by regional registry (15-35%, P<0.001),
there were no sigificant differences in the proportions offirst
three-digit site code discrepancies.
Morphology discrepancies
In 22(1.1%) cases, from the information in available medical
records, it was impossible to confirm the validity of the
originally alocated morphology codes. Among remaining
registrations, there were 566 (28.3%) discrepancies in ICD-O
(WHO, 1976) morphology coding. Discrepancies were classi-
fied into broad categories as shown in Table IV.
Almost half (49%) the discrepancies arose through
inferences about morphology (for example, made on the
basis of a chest radiograph) and allocation of morphology
codes when there was no evidence of histological or
cytological verification in the case records.
The proportions ofall discrepant morphology codes varied
signifiantly between regional registries (23-31%, P<0.05).
Death certificate only registrations (DCOs)
From the original sample of 2,200 registrtions, 57 (2.6%)
had been allocated institution codes (-888N) which desig-
Tabk I Numbers of cases originally registered to 1990 that were
reaIlocated, on record review, to different years of onset
Year of onset No. of cases Year of onset No. of cases
1974 1 1985 2
1978 1 (DCO) 1986 4
1980 1 1987 1
1981 1 (DCO) 1988 11 (3 DCOs)
1983 3 1989 72 (6 DCOs)
1984 1 1991 10
Table 11 Nature and distribution of ICD-9 site code discrepancies:
no. of cases (percentage of total study population with relevant
details recorded)
T1'pe of discrepancy
Subsiteunspecified recoded to a specific subsite
Dinepmey site(Amthdo "gis of
ICD4) cod)
Subsite unspecified recoded to 'other'
(overlappingsubsites)
Specificsubsite recoded to adifferent (specific)
subsite
Noevidenceofaneoplasmwarranting
registration'
Specificsubsite recoded to 'other' (overlapping
subsites)
Specific subsiterecoded tosubsiteunspecified
'Other' (overlapping subsites) recoded to a
specificsubsite
'Other' (overlapping subsites) recoded to subsite
unspecified
Total
No. of cases (%)
394(19.5%)
109(5.4%)
46(2.3%)
43(2.1%)
33(1.6%)
14(0.7%)
3(0.15%)
2(0.1%)
1(0.05%)
645(32%)
'Including benign tumours and recurrence of, or metastases from,
previously identified tumours.956 D. BREWSTER et al.
nated them as DCOs. However, four did not have recorded
dates of death. Primary care medical records were obtainable
for 39 (68.4%). The availability of medical records relating to
DCO registrations varied significantly by regional registry
(0-100%, P = 0.004).
Two of the 39 available DCOs, although having tumours
warranting registration, should not have been registered as
DCOs. One was resident in a health board adjacent to the
health board of registration and one, resulting from a biopsy
performed by the patient's general practitioner, had incor-
rectly been given the DCO institution code. Eighteen of the
remainder were judged to be 'avoidable' DCOs in so far as
they had been admitted to hospital at some stage of their
illness and should have generated a hospital discharge (Scot-
tish Morbidity Record 1 or SMR 1) form which, in turn,
should have triggered registration of their cancer. The
remaining 19 were judged to be 'unavoidable' (Table V).
Serious discrepancies
Of the 2,021 registrations with obtainable medical records, 57
(2.8%) cases were judged to contain serious discrepancies on
the basis that they should not have been held in the 1990
data set (Table VI). Registrations which were reallocated to
1989 or 1991 were regarded as misclassifications to adjacent
Table Ill Nature and distribution ofdiscrepancies affecting the first
three digits of the ICD-9 site code
Tipe of discrepancy No. of cases
Primary malignant neoplasm recoded to(different) 45
primary site'
Primary malignant neoplasm recoded to 16
metastases
Carcinoma in situ recoded toprimary malignant 11
neoplasm
Metastases recoded to metastases (different first 10
three-digit code)
Metastases recoded to malignant neoplasm of 7
otherand ill-defined sites
Metastases recoded toprimary malignant 5
neoplasm
Primary malignant neoplasm recoded to 4
carcinoma in situ
Primary malignant neoplasm recoded to neoplasm of 4
uncertain behaviour
Primary malignant neoplasm recoded tomalignant 3
neoplasm ofotherand ill-defined sites
Malignant neoplasm ofotherandill-defined sites I
recoded to metastases
Carcinoma in situ recoded to neoplasm of I
uncertain behaviour
Neoplasm ofuncertain behaviour recoded to I
primary malignant neoplasm
Neoplasm ofunspecified nature recoded to I
primary malignant neoplasm
Total 109
'Nineteen of these were recoded to (numerically) adjacent sites.
years (presumably occurring in a fairly random fashion over
time) and were not considered to be serious errors for this
reason alone. Likewise, discrepancies in the first three digits
ofthe ICD-9 site code were not regarded as serious errors for
this reason only, although some were of greater
epidemiological significance than others.
Dicussio
The distribution of various characteristics within the sample
suggests that it was reasonably representative of all registra-
tions of cancer in Scotland assigned to 1990. At 92%, the
Table V Reasons for 'unavoidable DCOs
Reason No. of cases
Diagnosis made on adomiciliary visit 5
Diagnosis made atout-patientclinic 4
Diagnosis madebygeneral practitioner 4
Incorrectdiagnosisgiven ondeath certificate I
Diagnosis notmentioned indischarge summary 2
Diagnosismadeatcasualtydepartment I
Diagnosis at Englishprivatehospital I
Autopsy initiatedby the Procurator Fiscal I
Total 19
'This patient was admitted to hospital with bowel obstruction and
found to have bladder cancer (which was duly registered). She was
transferred toahospice forterminalcare. Presumablyowingtoafailure
ofcommunication, the diagnosis recorded on her death certificate was
cancer of the colon leading to another, effectively duplicate but
erroneous registration.
Table VI Classification of serious discrepancies of registration
Type of discrepancy No. of cases
Yearofdiagnosis priorto 1989 15
Extremelydubious ornoevidenceofa neoplasm 14
warrantingregistration"
Not resident in Scotland atdiagnosis(twocases I1
werealsodiagnosed before 1989)
Reclassified from malignant to benign tumoursb 8
Metastases from previousprimary tumours 4
(all originallydiagnosed before 1989)
Incorrectdeathcertificate diagnosis (twocases 3
referred to tumoursdiagnosed before 1989)
Recurrence oftumourat previous excision site 2
(both originallydiagnosed before 1989)
Total 57
'Oneofthesecasesarosewhen thepatientwasadmitted tohospital in
1990andtheadmittingdoctorrecordedapasthistoryofprostatecancer
which was duly registered. Furtherenquiry at the time ofreabstraction
revealed a past history of bladder cancer diagnosed at a different
hospital in 1986 but no evidence of prostate cancer. bTwo additional
cases were reclassified as benign after reabstraction: one had originally
been registered as a neoplasm of uncertain behaviour; the other as a
neoplasm of unspecified nature.
Table IV Nature and distribution of ICD-O morphology code discrepancies: no. of cases (percentage of total
study population with relevant details recorded)
Originallyregisteredmorphology Reabstractedmorphology No. ofcases
Carcinoma NOS (not otherwisespecified) Morphologycodenotallocated3 182(9.1%)
Lowernumber ICD-0morphologycodeb Higher numberICD-0morphologycode 154(7.7%)
Carcinoma NOS MorespecificICD-0morphology code 82(4.1%)
Specific ICD-0morphologycode Morphologycodenotallocated' 48(2.4%)
Neoplasm NOS Morphologycode notallocated 46(2.3%)
Higher number ICD-0morphology code Lower number ICD-0morphologycode 38(1.9%)
Neoplasm NOS More specific ICD-0morphology code 16(0.8%)
Total 566(28.3%)
'Morphology had evidently been inferred at the time of original registration despite the apparent absence of
definitive histological or cytological verification. bNot including tumours originally coded as 'neoplasm NOS' or
'carcinoma NOS'. Whenmorethan onemorphologycodeseemed tobeapplicable,theonewith thehighestnumber
was allocated in accordance with ICD-O rules.ACCURACY OF SCOTTISH CANCER REGISrRATION DATA 957
availability of medical records compares favourably with a
similar study (West, 1976) in which only 81% of medical
records were traced. In view of the policy of some health
boards of destroying primary care records of patients
deceased for more than 2 or 3 years, it is not surprising that
a higher proportion of DCO registrations had unobtainable
records. The significant regional difference in total record
availability arose because of lower than average availability
in two major health boards (86% and 89%).
Reabstracted details may not represent everyone's inter-
pretation of the information held in patients' medical
records. Indeed, information in medical records, even histo-
pathological diagnoses, may sometimes be invalid (Saksela &
Rintala, 1968; Symmers, 1968; Hakama et al., 1973; Sax6n,
1979; Gray et al., 1987; Ullin et al., 1990). Nevertheless, the
reabstracted record method is regarded as the most objective
way of evaluating the accuracy of cancer registration data
(Parkin et al., 1992).
Comparison with other studies
Use of differing selection criteria and different ways of pre-
senting results means that comparisons with other studies are
not always straightforward. Furthermore, since the dis-
crepancy rate (except, perhaps, in identifying data) seems to
vary according to site (West, 1976; Polissar et al., 1984),
comparisons with single-site studies should be viewed with
caution. In this study, apart from cases for whom medical
records could not be retrieved, all patients were included in
the analysis of each item of data (and only rarely were
relevant details absent from available medical records). Thus,
the rate of discrepancies might be expected to be higher than
in other studies which exclude certain categories of patient
(such as DCOs).
Identifying data
The low rate of surname discrepancies (0.9%) is similar to
the 0.8% found by West (1976) in South Wales, although
twice as many first forename discrepancies were found in the
Welsh study (2.1%) as in this one (1.0%). Discrepancies in
gender were not recorded in Wales, but in two other studies
the discrepancy rate was higher at 1.0% (Polissar et al., 1984)
and 0.5% (Kee et al., 1992) than in Scotland (0.4%). Rates
of date of birth discrepancies reported from other studies
have been 11.2% (West, 1976), 4% (Polissar et al., 1984) and
7% (Gulliford et al., 1993), all higher than in Scotland
(1.3%).
More than one version (but including the registered ver-
sion) ofsurname spelling, forename spelling and date of birth
were found in the medical records of 2.2%, 2.3% and 2.6%
of cases respectively. Since these were not counted as dis-
crepancies, the true rate of inaccuracy in surname, forename
and date of birth may have been underestimated in this
study.
'Date treatment commenced' (anniversary date)
The choice of anniversary date has three important impli-
cations: firstly, it determines to which year's registration data
the neoplasm is allocated; secondly, it affects the caculation
of age at diagnosis; and, thirdly, it affects the calculation of
survival figures.
In this study, only 5% ofregistrations were reassigned to a
different year of incidence. Equivalent figures for other
studies were 7.6% (West, 1976), 0.5% of a sample of
leukaemia cases (Glass et al., 1987), 1.6% of a sample of
leukaemia cases (Baijal et al., 1989), 13.4% of a sample of
breast cancers (Kee et al., 1992) and 4.8% of a sample of
bladder cancers (Gulliford et al., 1993).
Discrepancies in anniversary date were particularly evident
in the case of non-melanoma skin tumours. This seemed to
depend on whether day case procedures had been mrgarded as
admissions to hospital. If, as in this study, they were not, the
(often much earlier) date of first attendance at out-patient
clinic was chosen as the anniversary date. The potential for
allocating quite different anniversary dates to non-melanoma
skin tumours may explain why, in terms of the proportion of
reabstacted records given anniversary dates within 6 weeks
of those originally recorded, regional variation became
insignificant when non-melanoma skin tumours were ex-
cluded from the analysis. Nevertheless, the observed regional
variation for all tumour sites suggests the use of variable
criteria to choose the anniversary date. Since some cancer
patients never receive treatment for their disease, we believe
that the term 'date treatment commenced' is misleading and
should be abandoned in favour of 'date of diagnosis' (which
is theoretically applicable to all patients). Rules governing the
choice of this date need to be expanded, perhaps in accord-
anice with those outlined for 'incidence date' in MacLennan
(1991).
Random misclassification to adjacent years is unlikely to
substantially distort time trends over a period of years, pro-
viding it occurs to a similar extent from year to year. How-
ever, tumours registered to 1990 that were actually incident
in the years before 1989 have greater potential to adversely
affect survival figures. Fortunately, such registrations formed
only 1.3% of the total study population.
Histological verification status
There is some evidence of confusion about what constitutes
histological verification. As with 'date treatment com-
menced', we believe that this stems partly from inadequate
guidelines but perhaps also from difficulties in achieving
uniformity of practice across five functionally independent
regional registries. An ideal solution would be to collect the
'most valid basis of diagnosis' as outlined in MacLennan
(1991). This was suggested during a recent review of the
Scottish Cancer Registration System (SHHD, 1990) and is
presently under consideration.
On occasion, the relevant pathology report was not in the
case notes of the registering hospital because the diagnosis
had already been made at a different hospital (and should
have been registered there). In such cases, histological
verification status (and, where available, morphology) had to
be derived from clinical notes or correspondence contained in
the medical records. Anniversary date was similarly difficult
to derive with precision for some of these patients. Since a
considerable proportion of patients seen at tertiary referral
centres have presumably been diagnosed at other hospitals,
rgistrations by tertiary centres imply a possible failure of
registration mechanisms in other hospitals and must raise
some concerns about completeness of case ascertainment
generally (Benn et al., 1982).
Site discrepancies
At first glance, a 32% rate of site coding discrepancies is
disappointing. Rates reported from other studies have been
16% (West, 1976), 38% of a sample of oral cancers (Frank-
lin, 1984), 27% (Polissar et al., 1984) and 26.4% (Lapham &
Waugh, 1992). The most important discrepancies are those
affecting the first three digits of the site code. In this study,
only 5.4% of registrations had discrepancies at this level.
Equivalent figures reported in previous studies have been
6.3% (West, 1976), 30% of a sample of oral cancers (Frank-
lin, 1984), 7% (Polissar et al., 1984) and 7.1% (Lapham &
Waugh, 1992).
Predictably, more than half (61%) of the observed site
discrepancies in this study were the result of failure to code
to a specific subsite. Sometimes, however, the subsite is not
explicitly stated in the medical records or, as noted elsewhere
(Lapham & Waugh, 1992), in the pathology report.
Difficulties can arise from conflicting opinions about
tumour location and the use of imprecise or ambiguous
diagnostic statements such as 'behind the ear' (posterior
aspect of pinna or skin of neck?) and 'below the nipple'
(subareolar or inferior in a caudal sense?)958 D. BREWSTER et al.
Morphology discrepancies
Although it is possible for a tumour to be histologically or
cytologically verified without such information ever reaching
the patient's medical records. this seems unlikely to occur in
most cases. Thus. the majority of what we have termed
*inferred' morphology codes are likely to have been genuinely
inferred in the absence of histological or cytological evidence.
Such cases could be readily identified if 'most valid basis of
diagnosis' was routinely collected.
The remainder of morphology coding discrepancies occur-
red in 14.5% of the study population. Error rates reported
from other studies have been 19.1% (West. 1976) and 16%
(Polissar et al.. 1984). Gulliford et al. (1993). in a selected
sample of bladder cancer registrations, reported that mor-
phology codes were broadly correct in 87% of cases but did
not distinguish between, for example, transitional cell car-
cinoma (ICD-O M8120) and papillary transitional cell car-
cinoma (ICD-O M8130).
Often. available information had not been fully extracted
from pathology reports. While the commoner types of cancer
were usually coded correctly, the use of adjectival qualifiers
sometimes caused problems. This seemed to occur when des-
criptions. such as 'mucin producing', were contained within
the text of the pathology report but not in the diagnostic
summary statement.
Death certificate onl/ registrations (DCOs)
The fact that primary care medical records were obtainable
for 68% of the DCO registrations is encouraging, and this
figure would presumably have been higher if all records had
been sought within 2 years of death. The overall standard of
record keeping in primary care was high, although it was
uncommon for copies of relevant pathology reports to be
contained in the general practitioners' notes.
A study of death certificates in the United States (Percy et
al.. 1981) has shown that doctors tend to report a non-
specific site in cancer patients rather than the specific site
identified in the medical records. This was evident even from
the relatively small group of DCOs with obtainable records
(39) in this study, nine of whom were recoded from subsite
unspecified to a specific subsite. The ready availability of
other information in primary care records suggests that more
active follow-up of DCO registrations would be worthwhile.
It is a cause for concern that 18 patients had been admit-
ted to hospital at some stage of their illness yet their tumours
were only registered on the basis of their death certificates.
This may also reflect less than complete ascertainment of
cases among other patients who have been admitted to hos-
pital but are still alive.
Serious discrepancies
It is disappointing that. on reabstraction, 57 cases (2.8%)
were judged to present serious discrepancies, only six being
accounted for by DCO registrations. The potential impact of
these types of discrepancies on incidence and survival data is
variable. For example, as discussed previously, tumours
wrongly attributed to 1990 that were actually first diagnosed
in the years before 1989 will tend to adversely affect survival
figures. Conversely, registrations of malignant neoplasms
which are either spurious or benign will tend to falsely
prolong survival. Registration of any tumour that is not
eligible for registration will, of course, have an inflationary
effect on incidence figures.
Most of the serious discrepancies have arisen through
over-registration and may indicate an implicit emphasis on
not missing any cases at the expense of accuracy. Perhaps
this is a reflection of the currently available coding guide.
which states how to register cases but does not explicitly list
reasons for not registering a tumour.
However, some of the discrepancies arose because of
revisions of diagnosis following registration. This illustrates
the hazard ofregistering a tumour too soon and the potential
trade-off between timeliness and accuracy. Thus, the current
pressure for timely hospital discharge data to serve the pur-
chaser-provider function (Ferguson et al., 1993) may also
have implications for cancer registration. More than ever,
there is a need for a failsafe mechanism to transmit revisions
of clinical and pathological diagnosis to the cancer registry.
Variation bY regional registry
Although references to variation by regional registry have
been made throughout the presentation of results, it should
be remembered that this study was not primarily designed to
measure such variation (in which case, a stratified sample
would have been drawn). Nevertheless, the fact that regional
variation in the level of discrepancies was observed could
have implications for studies of geographical variations in
incidence and survival. However. it is reassuring to note that
there was no evidence of significant regional variation in-
terms of site code (the first three digits) nor (for malignant
neoplasms excluding non-melanoma skin tumours) anniver-
sary date (within 6 weeks). Furthermore. when regional
vranation in discrepancy rates were observed. no single regis-
try performed consistently poorly.
Conclusion
In many respects. Scottish Cancer Registration data show a
high level of accuracy. This should be reassuring to those
involved in exploratory epidemiological studies of commonly
occurring cancers and in the assessment of needs for cancer
services. However, we have identified a number of problem
areas which are currently being considered in the context of a
wider review of the structure and mechanisms of cancer
registration in Scotland.
(A more detailed account of this study and its results is
available, on request, from the authors.)
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Appendix
Rules for selecting date treatment commenced were as follows:
* For patients who have received in-patient care - insert date of
first admission for investigation or treatment.
* For patients who have received out-patient care only, i.e. with no
record of in-patient care for this cancer - insert date of first
out-patient consultation.
* For patients who have received domiciliary care only (i.e. with no
record of hospital care (out-patient or in-patient) for this cancer)
- insert date of diagnosis (or estimated date).